Skip to main content

Table 3 Co-morbidities in the respondents with and without BA

From: The prevalence, burden and risk factors associated with bronchial asthma in commonwealth of independent states countries (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

 

Ukraine

Kazakhstan

Azerbaijan

 

Respondentsa

 

Respondentsa

 

Respondentsa

 
 

without BA

with BA

p-value

without BA

with BA

p-value

without BA

with BA

p-value

Valid N

871

70

 

693

237

 

817

115

 

Any co-morbidity, %

42.0

62.9

0.001

20.8

50.6

< 0.001

51.4

77.4

< 0.001

Hypertension, %

13.1

37.1

< 0.001

21.6

40.1

< 0.001

16.2

27.0

0.006

Diabetes, %

3.2

5.7

0.291

3.5

4.2

0.689

4.8

9.6

0.044

Cardiovascular disease, %

6.0

14.3

0.013

7.0

13.9

0.001

3.5

8.7

0.015

Abnormal blood lipids, %

4.3

10.0

0.039

10.0

17.3

0.004

1.0

3.5

0.050

Depression, %

0.5

1.4

0.322

0.4

0.8

0.607

1.7

3.5

0.263

Anxiety, %

0.2

0.0

1.000

0.6

0.4

1.000

2.6

3.5

0.758

Osteoporosis, %

0.6

1.4

0.374

1.5

2.5

0.384

0.5

0.9

1.000

Tuberculosis, %

0.5

1.4

0.321

2.2

1.7

0.794

0.7

7.0

< 0.001

Pneumonia, %

18.9

38.6

< 0.001

11.8

27.8

< 0.001

5.5

12.2

0.009

Allergic rhinitis, %

3.6

15.7

< 0.001

5.6

21.9

< 0.001

6.9

20.9

< 0.001

  1. a Respondents with BA are respondents who reported wheezing symptoms at the ATS Respiratory Symptoms Questionnaire
  2. Percentages are calculated from the number of respondents with valid data (valid N). P-values are for the 2-sided comparison (Chi-square tests) of rates between respondents with and without BA
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us